News
-
Liquidia Technologies has named Jeri Thomas as its new Senior VP Commercial, responsible initially for commercial plans for the company’s LIQ861 treprostinil DPI, which is currently in Phase 3 development for the treatment of pulmonary… Read more . . .
-
The FDA has accepted Insned’s NDA for ALIS (amikacin liposome inhalation suspension) for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC), with a PDUFA date of September 28, 2018,… Read more . . .
-
The FDA informed Perrigo during a May 10, 2018 teleconference that the agency will issue a complete response letter to the company’s ANDA for its generic version of Teva’s ProAir albuterol MDI, Perrigo said. As… Read more . . .
-
MannKind Corporation announced that it has signed a deal with Cipla for marketing and distribution of Afrezza inhaled insulin in India. Cipla will be responsible for getting regulatory approval in India and will pay MannKind… Read more . . .
-
The Medical Devices Group at the University of Cape Town has designed a device to significantly reduce the force required to actuate an inhaler, the university has announced. The device, called “Easy Squeezy,” fits over… Read more . . .
-
TFF Pharmaceuticals, which recently announced that it had raised $14 million for the development of DPI formulations, has named former Arno Therapeutics CEO Glenn Mattes as its new Chief Executive Officer. Mattes’s career includes management… Read more . . .
-
US biopharmaceutical company NanoBio Corporation has changed its name to BlueWillow Biologics, which the company says “reflects its evolution to a vaccines-focused company, and commitment to advancing its novel intranasal technology to develop new vaccines… Read more . . .
-
Janssen Pharmaceutical has announced that data from a Phase 3 study demonstrated significantly significant and clinically meaningful reduction of symptoms in adult patients with treatment-resistant depression who received esketamine nasal spray plus an oral antidepressant… Read more . . .
-
Engage Therapeutics has announced the initiation of the double-blind, randomized Phase 2b StATES (Staccato Alprazolam Terminates Epileptic Seizures) trial of inhaled alprazolam in epilepsy patients who have seizures with a predictable pattern. The company said… Read more . . .
-
Approximately 550 OINDP specialists attended RDD 2018 in Tucson, Arizona, where much of the interest centered around regulatory issues, especially in light of the FDA’s recent release of a revised draft guidance on MDI and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany